Cargando…

Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry

OBJECTIVE: To evaluate the impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany. DESIGN: This study employs real-world data captured in-time during clinical visits in 67 German neurology outpatient offices of the NeuroTransData (NTD) multipl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braune, Stefan, Rossnagel, Fabian, Dikow, Heidi, Bergmann, Arnfin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336188/ https://www.ncbi.nlm.nih.gov/pubmed/34344670 http://dx.doi.org/10.1136/bmjopen-2020-042480

Ejemplares similares

The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry
por: Braune, Stefan, et al.
Publicado: (2023)

How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?
por: Braune, Stefan, et al.
Publicado: (2022)

Implementation of a data control framework to ensure confidentiality, integrity, and availability of high-quality real-world data (RWD) in the NeuroTransData (NTD) registry
por: Wehrle, Knut, et al.
Publicado: (2022)

The socioeconomic impact of disability progression in multiple sclerosis: A retrospective cohort study of the German NeuroTransData (NTD) registry
por: Dillon, Paul, et al.
Publicado: (2023)

COVID-19: Status neurologischer und psychiatrischer Praxen am Beispiel des Netzwerks NeuroTransData
por: Bergmann, Arnfin
Publicado: (2020)

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry
por: Braune, Stefan, et al.
Publicado: (2018)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
por: Lesage, E., et al.
Publicado: (2010)

PHREND(®)—A Real-World Data-Driven Tool Supporting Clinical Decisions to Optimize Treatment in Relapsing-Remitting Multiple Sclerosis
por: Braune, Stefan, et al.
Publicado: (2022)

Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry
por: Jiang, Xiaotong, et al.
Publicado: (2023)

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)
por: Gold, Ralf, et al.
Publicado: (2015)

Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens
por: Rodi, Maria, et al.
Publicado: (2016)

Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
por: Feng, Jenny, et al.
Publicado: (2019)

Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis
por: Stühler, E., et al.
Publicado: (2020)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
por: Braune, Stefan, et al.
Publicado: (2015)

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
por: Braune, Stefan, et al.
Publicado: (2013)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Development of Registry Data to Create Interactive Doctor-Patient Platforms for Personalized Patient Care, Taking the Example of the DESTINY System
por: Bergmann, Arnfin, et al.
Publicado: (2021)

The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial
por: Metzger-Peter, Katline, et al.
Publicado: (2020)

Polymorphonuclear Cell Functional Impairment in Relapsing Remitting Multiple Sclerosis Patients: Preliminary Data
por: Allizond, Valeria, et al.
Publicado: (2015)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis
por: Perrone, Valentina, et al.
Publicado: (2022)

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
por: Casanova, Bonaventura, et al.
Publicado: (2017)

Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data
por: Ohlmeier, Christoph, et al.
Publicado: (2020)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Defective structural RNA processing in relapsing-remitting multiple sclerosis
por: Spurlock, Charles F, et al.
Publicado: (2015)

Thalamic–hippocampal–prefrontal disruption in relapsing–remitting multiple sclerosis
por: Kern, Kyle C., et al.
Publicado: (2014)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Sexual dysfunction in female patients with relapsing‐remitting multiple sclerosis
por: Bartnik, Pawel, et al.
Publicado: (2017)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

Circadian Activity Rhythm in Early Relapsing–Remitting Multiple Sclerosis
por: Tonetti, Lorenzo, et al.
Publicado: (2019)

Systematic review of prediction models in relapsing remitting multiple sclerosis
por: Brown, Fraser S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5h2bakcgi907jhn6moqgch917m